Brainstorm Cell Therapeutics Stock Beta
| GHDN Stock | EUR 2.69 0.00 0.00% |
Brainstorm Cell Therapeutics fundamentals help investors to digest information that contributes to Brainstorm Cell's financial success or failures. It also enables traders to predict the movement of Brainstorm Stock. The fundamental analysis module provides a way to measure Brainstorm Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brainstorm Cell stock.
Brainstorm |
Brainstorm Cell Therapeutics Company Beta Analysis
Brainstorm Cell's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Brainstorm Cell Beta | -0.36 |
Most of Brainstorm Cell's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brainstorm Cell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Brainstorm Cell Therapeutics has a Beta of -0.3612. This is 142.0% lower than that of the Healthcare sector and 125.99% lower than that of the Biotechnology industry. The beta for all Germany stocks is 140.8% higher than that of the company.
Brainstorm Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brainstorm Cell's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Brainstorm Cell could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics of similar companies.Brainstorm Cell is currently under evaluation in beta category among its peers.
As returns on the market increase, returns on owning Brainstorm Cell are expected to decrease at a much lower rate. During the bear market, Brainstorm Cell is likely to outperform the market.
Brainstorm Fundamentals
| Return On Equity | -1.93 | |||
| Return On Asset | -0.68 | |||
| Current Valuation | 44.56 M | |||
| Shares Outstanding | 36.54 M | |||
| Shares Owned By Insiders | 22.70 % | |||
| Shares Owned By Institutions | 10.41 % | |||
| Price To Book | 36.30 X | |||
| EBITDA | (24.28 M) | |||
| Net Income | (24.46 M) | |||
| Cash And Equivalents | 6.22 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 3.04 M | |||
| Debt To Equity | 934.00 % | |||
| Current Ratio | 0.97 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (26.27 M) | |||
| Earnings Per Share | (0.68) X | |||
| Target Price | 11.5 | |||
| Number Of Employees | 43 | |||
| Beta | -0.36 | |||
| Market Capitalization | 74.73 M | |||
| Total Asset | 29.28 M | |||
| Z Score | 14.4 | |||
| Net Asset | 29.28 M |
About Brainstorm Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Brainstorm Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Brainstorm Stock
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.